Newron Pharmaceuticals S.p.A.
NWPHF · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $51 | $9 | $6 | $6 |
| % Growth | 467.4% | 48.6% | 5.8% | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $51 | $9 | $6 | $6 |
| % Margin | 100% | 100% | 100% | 100% |
| R&D Expenses | $14 | $13 | $12 | $11 |
| G&A Expenses | $7 | $4 | $4 | $3 |
| SG&A Expenses | $7 | $4 | $4 | $4 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $4 | $3 | $0 | $0 |
| Operating Expenses | $25 | $21 | $20 | $18 |
| Operating Income | $26 | -$12 | -$13 | -$12 |
| % Margin | 50.9% | -128.4% | -218.3% | -214.5% |
| Other Income/Exp. Net | -$5 | -$5 | -$4 | -$3 |
| Pre-Tax Income | $21 | -$16 | -$17 | -$15 |
| Tax Expense | $6 | $0 | $0 | $0 |
| Net Income | $16 | -$16 | -$17 | -$15 |
| % Margin | 30.8% | -179.1% | -287.1% | -258.6% |
| EPS | 0.85 | -0.91 | -0.98 | -0.84 |
| % Growth | 193.4% | 7.1% | -16.7% | – |
| EPS Diluted | 0.85 | -0.91 | -0.98 | -0.84 |
| Weighted Avg Shares Out | 19 | 18 | 18 | 18 |
| Weighted Avg Shares Out Dil | 19 | 18 | 18 | 18 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $3 |
| Interest Expense | $4 | $4 | $4 | $3 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | $26 | -$12 | -$13 | -$12 |
| % Margin | 50.5% | -130.6% | -218.6% | -204% |